COLL Valuation

Collegium Pharmaceutical Inc

Add to Watchlist

Advanced Chart

27.010

+0.120(+0.450%)

Overview
Forecast
Valuation

COLL Relative Valuation

COLL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, COLL is overvalued; if below, it's undervalued.

Historical Valuation

Collegium Pharmaceutical Inc (COLL) is now in the Undervalued zone, suggesting that its current forward PE ratio of 3.90 is considered Undervalued compared with the five-year average of 4.73. The fair price of Collegium Pharmaceutical Inc (COLL) is between 61.50 to 72.80 according to relative valuation methord. Compared to the current price of 27.01 USD , Collegium Pharmaceutical Inc is Undervalued By 56.08%.

Relative Value

Fair Zone

61.50-72.80

Current Price：27.01

56.08%

Undervalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

3.70

P/B

Median3y

4.34

Median5y

4.12

23.43

FCF Yield

Median3y

21.13

Median5y

17.31

Competitors Valuation Multiple

The average P/S ratio for COLL's competitors is 208.27, providing a benchmark for relative valuation. Collegium Pharmaceutical Inc Corp (COLL) exhibits a P/S ratio of 1.17, which is -99.44% above the industry average. Given its robust revenue growth of 21.51%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

COLL.O

Collegium Pharmaceutical Inc

1.17

Average P/S: 208.27

21.51%